keyword
https://read.qxmd.com/read/38696033/emerging-dna-methylome-targets-in-flt3-itd-positive-acute-myeloid-leukemia-combination-therapy-with-clinically-approved-flt3-inhibitors
#1
REVIEW
Melisa Tecik, Aysun Adan
The internal tandem duplication (ITD) mutation of the FMS-like receptor tyrosine kinase 3 (FLT3-ITD) is the most common mutation observed in approximately 30% of acute myeloid leukemia (AML) patients. It represents poor prognosis due to continuous activation of downstream growth-promoting signaling pathways such as STAT5 and PI3K/AKT. Hence, FLT3 is considered an attractive druggable target; selective small FLT3 inhibitors (FLT3Is), such as midostaurin and quizartinib, have been clinically approved. However, patients possess generally poor remission rates and acquired resistance when FLT3I used alone...
May 2, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38695847/clinicopathologic-conference-bloodstream-infection-in-an-allogeneic-hamatopoietic-cell-transplant-thinking-beyond-the-usual
#2
JOURNAL ARTICLE
Kim Yeoh, Cornelia Lass-Flörl, Frédéric Lamoth, Monica A Slavin, Eloise Williams, Dionysios Neofytos
This case involves a 53-year-old female with concurrent acute myeloid leukemia (AML) and multiple myeloma. She underwent cytarabine and daunorubicin (7+3) induction chemotherapy followed by cytarabine (HiDAC) consolidation, with an early AML relapse requiring azacitidine and venetoclax therapy. She achieved complete remission and incomplete count recovery. Following fludarabine, melphalan, and thymoglobulin induction chemotherapy, she underwent an allogeneic stem cell transplant with failure to engraft, requiring autologous stem cell rescue, buffy coat, and granulocyte transfusions, eventually presenting with a diffuse skin rash consistent with Steven-Johnson syndrome and toxic epidermal necrolysis, persistent neutropenic fevers and positive blood cultures...
May 2, 2024: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/38695592/ultraviolet-light-emitting-diode-radiation-kills-leukemia-cells-without-affecting-hematopoiesis-of-hematopoietic-stem-cells-in-mice
#3
COMPARATIVE STUDY
Dong Xie, Lirong Sun, Xingqing Guo, Jian Jiang, Yan Sun, Jiandong Sun
OBJECTIVES: The eradication of leukemia cells while sparing hematopoietic stem cells in the graft before autologous hematopoietic stem cell transplant is critical to prevention of leukemia relapse. Proliferating cells have been shown to be more prone to apoptosis than differentiated cells in response to ultraviolet radiation; however, whether leukemia cells are more sensitive to ultraviolet LED radiation than hematopoietic stem cells remains unclear. MATERIALS AND METHODS: We compared the in vitro responses between murine leukemia L1210 cells and murine hematopoietic stem cells to 280-nm ultraviolet LED radiation...
March 2024: Experimental and Clinical Transplantation
https://read.qxmd.com/read/38695148/recent-advances-on-anti-hiv-chimeric-antigen-receptor-t-cell-treatment-to-provide-sustained-hiv-remission
#4
JOURNAL ARTICLE
Hang Su, April Mueller, Harris Goldstein
PURPOSE OF REVIEW: Successful sustained remission of HIV infection has been achieved after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation for treatment of leukemia in a small cohort of people living with HIV (PLWH). This breakthrough demonstrated that the goal of curing HIV was achievable. However, the high morbidity and mortality associated with bone marrow transplantation limits the routine application of this approach and provides a strong rationale for pursuing alternative strategies for sustained long-term antiretroviral therapy (ART)-free HIV remission...
May 2, 2024: Current Opinion in HIV and AIDS
https://read.qxmd.com/read/38695144/outcomes-and-genetic-dynamics-of-acute-myeloid-leukemia-at-first-relapse
#5
JOURNAL ARTICLE
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, Tapan Kadia, Naval Daver, Courtney D DiNardo, Gautam Borthakur, Sanam Loghavi, Keyur Patel, Guilin Tang, Koji Sasaki, Nicholas J Short, Musa Yilmaz, Ghayas C Issa, Yesid Alvarado, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A Abbas, Koichi Takahashi, Sherry Pierce, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi
Patients with relapsed acute myeloid leukemia (rAML) experience dismal outcomes. We performed a comprehensive analysis of patients with rAML to determine the genetic dynamics and survival predictive factors. We analyzed 875 patients with newly diagnosed AML who received intensive treatment (IT) or low-intensity treatment (LIT). Of these patients, 197 experienced subsequent rAML. Data was available for 164 patients, with a median time from CR/CRi to relapse of 6.5 months. Thirty-five of the 164 patients (21%) experienced relapse after allogeneic hematopoietic stem cell transplantation (alloSCT)...
May 2, 2024: Haematologica
https://read.qxmd.com/read/38694825/chimeric-antigen-receptor-car-modified-t-cells-in-acute-myeloid-leukemia-limitations-and-expectations
#6
REVIEW
Beatriz Guijarro-Albaladejo, Cristina Marrero-Cepeda, Eduardo Rodríguez-Arbolí, Belén Sierro-Martínez, José Antonio Pérez-Simón, Estefanía García-Guerrero
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for patients with relapsed/refractory (R/R) AML. In recent years, it has been possible to individualize the treatment of a subgroup of patients, particularly with the emergence of multiple targeted therapies. Nonetheless, a considerable number of patients remain without therapeutic options, and overall prognosis remains poor because of a high rate of disease relapse...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38694447/adverse-events-of-cell-therapy-clinical-trials-in-human-chronic-spinal-cord-injury-a-systematic-review-and-meta-analysis
#7
REVIEW
Esmat Davoudi-Monfared, Reyhaneh Abolghasemi, Fakhri Allahyari, Gholamreza Farzanegan
Spinal cord injury is a lesion with high mortality and significant morbidities. After the primary injury, during six months, a cascade of secondary cellular and molecular events makes the lesion chronic. Recently, cell-based clinical trials as a new procedure have been gradually tested to improve the symptoms of patients. Each treatment method is associated with different adverse events. Based on the PRISMA flow diagram of the identified records, and after multistep screening, finally in 76 reviewed studies with 1633 cases and 189 controls, 64 types of adverse events in 12 categories were recorded in 45 studies...
December 2024: Regenerative Therapy
https://read.qxmd.com/read/38693565/inhibition-of-caspase-pathways-limits-cd4-t-cell-loss-and-restores-host-anti-retroviral-function-in-hiv-1-infected-humanized-mice-with-augmented-lymphoid-tissue
#8
JOURNAL ARTICLE
Alex J Holloway, Tais B Saito, Kubra F Naqvi, Matthew B Huante, Xiuzhen Fan, Joshua G Lisinicchia, Benjamin B Gelman, Janice J Endsley, Mark A Endsley
The study of HIV infection and pathogenicity in physical reservoirs requires a biologically relevant model. The human immune system (HIS) mouse is an established model of HIV infection, but defects in immune tissue reconstitution remain a challenge for examining pathology in tissues. We utilized exogenous injection of the human recombinant FMS-like tyrosine kinase 3 ligand (rFLT-3 L) into the hematopoietic stem cell (HSC) cord blood HIS mouse model to significantly expand the total area of lymph node (LN) and the number of circulating human T cells...
May 2, 2024: Retrovirology
https://read.qxmd.com/read/38693419/evolution-of-natural-killer-cell-targeted-therapy-for-acute-myeloid-leukemia
#9
REVIEW
Yuta Kaito, Yoichi Imai
In hematologic oncology, acute myeloid leukemia (AML) presents a significant challenge due to its complex genetic landscape and resistance to conventional therapies. Despite advances in treatment, including intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis for many patients with AML remains poor. Recently, immunotherapy has emerged as a promising approach to improve outcomes by augmenting existing treatments. Natural killer (NK) cells, a subset of innate lymphoid cells, have garnered attention for their potent cytotoxic capabilities against AML cells...
May 1, 2024: International Journal of Hematology
https://read.qxmd.com/read/38693109/macrophage-depletion-overcomes-human-hematopoietic-cell-engraftment-failure-in-zebrafish-embryo
#10
JOURNAL ARTICLE
Reine El Omar, Naoill Abdellaoui, Safiatou T Coulibaly, Laura Fontenille, François Lanza, Christian Gachet, Jean-Noel Freund, Matteo Negroni, Karima Kissa, Manuela Tavian
Zebrafish is widely adopted as a grafting model for studying human development and diseases. Current zebrafish xenotransplantations are performed using embryo recipients, as the adaptive immune system, responsible for host versus graft rejection, only reaches maturity at juvenile stage. However, transplanted primary human hematopoietic stem/progenitor cells (HSC) rapidly disappear even in zebrafish embryos, suggesting that another barrier to transplantation exists before the onset of adaptive immunity. Here, using a labelled macrophage zebrafish line, we demonstrated that engraftment of human HSC induces a massive recruitment of macrophages which rapidly phagocyte transplanted cells...
May 1, 2024: Cell Death & Disease
https://read.qxmd.com/read/38693089/high-cd34-positive-cell-dose-in-matched-unrelated-donor-allogeneic-hematopoietic-stem-cell-transplant-is-not-associated-with-graft-versus-host-disease-or-mortality
#11
JOURNAL ARTICLE
Zachary M Avigan, Ajoy L Dias, Laura E Dodge, Jon E Arnason, Robin M Joyce, Jessica Liegel, Jacalyn Rosenblatt, Matthew J Weinstock, David E Avigan, Richard L Haspel
BACKGROUND: CD34+ stem cells serve as the primary graft source for allogeneic transplants, with a minimum of 2-4 × 106 cells/kg needed for engraftment. There are conflicting data on outcomes at high stem cell doses, with studies limited by few patients receiving doses far above the minimum target. STUDY DESIGN AND METHODS: In this retrospective, single-center study of patients with hematologic malignancies who underwent matched unrelated donor transplants, we assessed outcomes for engraftment, survival, relapse, and graft-versus-host disease (GVHD) for the highest CD34+ dose quintile (>13 × 106 cells/kg, n = 36) compared to the remaining patients (n = 139)...
May 1, 2024: Transfusion
https://read.qxmd.com/read/38692825/combined-effects-of-clonal-hematopoiesis-and-carotid-stenosis-on%C3%A2-cardiovascular-mortality
#12
JOURNAL ARTICLE
Roland Jäger, Matthias Hoke, Florian J Mayer, Stefanie Boden, Cornelia Englisch, Cihan Ay, Robert Kralovics, Christoph J Binder
BACKGROUND: The expansion of hematopoietic stem cells caused by acquired somatic mutations (clonal hematopoiesis [CH]) is a novel cardiovascular risk factor. The prognostic value of CH in patients with carotid atherosclerosis remains to be evaluated. OBJECTIVES: This study assessed the prognostic significance of CH in patients with atherosclerosis as detected by ultrasound of the carotid artery. METHODS: We applied deep sequencing of selected genomic regions within the genes DNMT3A, TET2, ASXL1, and JAK2 to screen for CH in 968 prospectively collected patients with asymptomatic carotid atherosclerosis evaluated by duplex sonography...
May 7, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38692061/the-roles-of-epigenetic-regulation-in-graft-versus-host-disease
#13
REVIEW
Yimin Wang, Qi Liu, Lei Deng, Xiting Ma, Yuling Gong, Yifei Wang, Fang Zhou
Allogeneic hematopoietic stem cell transplantation (aHSCT) is utilized as a potential curative treatment for various hematologic malignancies. However, graft-versus-host disease (GVHD) post-aHSCT is a severe complication that significantly impacts patients' quality of life and overall survival, becoming a major cause of non-relapse mortality. In recent years, the association between epigenetics and GVHD has garnered increasing attention. Epigenetics focuses on studying mechanisms that affect gene expression without altering DNA sequences, primarily including DNA methylation, histone modifications, non-coding RNAs (ncRNAs) regulation, and RNA modifications...
April 30, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38691622/early-skeletal-outcomes-after-hematopoietic-stem-and-progenitor-cell-gene-therapy-for-hurler-syndrome
#14
JOURNAL ARTICLE
Giulia Consiglieri, Francesca Tucci, Maurizio De Pellegrin, Barbara Guerrini, Alessandro Cattoni, Giulia Risca, Stefano Scarparo, Marina Sarzana, Silvia Pontesilli, Renata Mellone, Serena Gasperini, Stefania Galimberti, Paolo Silvani, Chiara Filisetti, Silvia Darin, Giulia Forni, Simona Miglietta, Ludovica Santi, Marcella Facchini, Ambra Corti, Francesca Fumagalli, Maria Pia Cicalese, Valeria Calbi, Maddalena Migliavacca, Federica Barzaghi, Francesca Ferrua, Vera Gallo, Salvatore Recupero, Daniele Canarutto, Matteo Doglio, Lucia Tedesco, Nicola Volpi, Attilio Rovelli, Giancarlo la Marca, Maria Grazia Valsecchi, Stefano Zancan, Fabio Ciceri, Luigi Naldini, Cristina Baldoli, Rossella Parini, Bernhard Gentner, Alessandro Aiuti, Maria Ester Bernardo
Mucopolysaccharidosis type I Hurler (MPSIH) is characterized by severe and progressive skeletal dysplasia that is not fully addressed by allogeneic hematopoietic stem cell transplantation (HSCT). Autologous hematopoietic stem progenitor cell-gene therapy (HSPC-GT) provides superior metabolic correction in patients with MPSIH compared with HSCT; however, its ability to affect skeletal manifestations is unknown. Eight patients with MPSIH (mean age at treatment: 1.9 years) received lentiviral-based HSPC-GT in a phase 1/2 clinical trial (NCT03488394)...
May 2024: Science Translational Medicine
https://read.qxmd.com/read/38691145/combining-serum-micrornas-and-machine-learning-algorithms-for-diagnosing-infectious-fever-after-hsct
#15
JOURNAL ARTICLE
Wenwei Shao, Yixuan Wang, Li Liu, Yiran Ren, Jieru Wang, Yuqing Cui, Jia Liu, Xiaoyu Zhang, Sudong Zhang, Shuangjie Liu, Erlie Jiang, Sizhou Feng, Xiaolei Pei
Infection post-hematopoietic stem cell transplantation (HSCT) is one of the main causes of patient mortality. Fever is the most crucial clinical symptom indicating infection. However, current microbial detection methods are limited. Therefore, timely diagnosis of infectious fever and administration of antimicrobial drugs can effectively reduce patient mortality. In this study, serum samples were collected from 181 patients with HSCT with or without infection, as well as the clinical information. And more than 80 infectious-related microRNAs in the serum were selected according to the bulk RNA-seq result and detected in the 345 time-pointed serum samples by Q-PCR...
May 1, 2024: Annals of Hematology
https://read.qxmd.com/read/38690520/risk-factors-predicting-need-for-the-pediatric-intensive-care-unit-picu-post-hematopoietic-cell-transplant-picu-utilization-and-outcomes-following-hct-a-single-center-retrospective-analysis
#16
JOURNAL ARTICLE
Amanda K Johnson, Sinziana Cornea, Samuel Goldfarb, Qing Cao, Julia A Heneghan, Ashish O Gupta
Hematopoietic cell transplant (HCT) is a curative treatment for multiple malignant and non-malignant disorders. While morbidity and mortality have decreased significantly over the years, some patients still require management in the pediatric intensive care unit (PICU) during their HCT course for additional respiratory, cardiovascular, and/or renal support. We retrospectively reviewed pediatric patients (0-18 years) who underwent HCT from January 2015-December 2020 at our institution to determine risk factors for PICU care and evaluate PICU utilization and outcomes...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38690514/unveiling-the-role-of-hypoxia-inducible-factor-2alpha-in-osteoporosis-implications-for-bone-health
#17
JOURNAL ARTICLE
Ling-Ling Wang, Zhan-Jin Lu, Shun-Kui Luo, Yun Li, Zhe Yang, Hong-Yun Lu
BACKGROUND: Osteoporosis (OP) has become a major public health problem worldwide. Most OP treatments are based on the inhibition of bone resorption, and it is necessary to identify additional treatments aimed at enhancing osteogenesis. In the bone marrow (BM) niche, bone mesenchymal stem cells (BMSCs) are exposed to a hypoxic environment. Recently, a few studies have demonstrated that hypoxia-inducible factor 2alpha (HIF-2α) is involved in BMSC osteogenic differentiation, but the molecular mechanism involved has not been determined...
April 26, 2024: World Journal of Stem Cells
https://read.qxmd.com/read/38689819/recurrent-diffuse-alveolar-hemorrhage-and-extracorporeal-membrane-oxygenation-utilization-in-a-hematopoietic-stem-cell-transplant-patient-with-hunter-s-syndrome
#18
Nasreen Noor, Gene Peir, Ásdís Finnsdóttir Wagner, Jay Rilinger, Jenna Miller
We describe the natural history of a three-month-old patient with Hunter Syndrome with hematopoietic stem cell transplant (HSCT) who developed recurrent diffuse alveolar hemorrhage (DAH) requiring extracorporeal membrane oxygenation (ECMO). The patient underwent HSCT with several complications, including veno-occlusive disease and DAH. He was managed with ECMO. Unfortunately, despite initial success he developed recurrent DAH and ultimately died. This is a novel report of this severe adverse event requiring ECMO following the use of HSCT in this rare patient population...
2024: Archive of clinical cases
https://read.qxmd.com/read/38689598/the-role-of-extracorporeal-photopheresis-in-the-management-of-graft-versus-host-disease-narrative-review
#19
REVIEW
Ayenew Berhan, Shewaneh Damtie, Andargachew Almaw, Biruk Legesse, Bekele Sharew, Birhanu Getie, Mulat Erkihun, Yenealem Solomon
Hematopoietic stem cell donation is a method used to treat both blood-related and non-blood-related malignancies. Graft-versus-host disease is a potentially life-threatening complication that can occur following a stem cell transplant from a donor. This happens after the transplanted grafts attack the recipient's body as foreign cells, causing significant morbidity and mortality. Clinically, this condition can be classified as acute or chronic based on onset and pathophysiology. This review aims to provide an overview of recent studies on extracorporeal photopheresis as a treatment strategy option for graft-versus-host-diseased patients...
2024: ImmunoTargets and Therapy
https://read.qxmd.com/read/38689559/-myeloid-mutations-in-all-are-not-uncommon-implications-for-etiology-and-therapies
#20
REVIEW
Ilaria Iacobucci
In Blood Cancer Discovery, Saygin and colleagues report that somatic variants that are recurrent in myeloid malignancies can also occur with high frequency (16%) in adult acute lymphoblastic leukemia (ALL) where they correlate with older age, diagnosis following genotoxic therapy for a prior malignancy and worse outcome to chemotherapy. Mutations in these "myeloid" genes can precede ALL diagnosis and arise in hematopoietic stem or progenitor cells that clonally expand and differentiate into both lymphoblasts and nonmalignant myeloid cells, supporting a role for clonal hematopoiesis as premalignant state outside the context of myeloid malignancies and providing implications for both ALL etiology and therapeutic intervention...
May 1, 2024: Blood cancer discovery
keyword
keyword
394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.